Alkermes plc 8AK.F Stock
Alkermes plc Price Chart
Alkermes plc 8AK.F Financial and Trading Overview
Alkermes plc stock price | 23 EUR |
Previous Close | 28.6 EUR |
Open | 28.6 EUR |
Bid | 28.6 EUR x N/A |
Ask | 29.8 EUR x N/A |
Day's Range | 28.6 - 28.6 EUR |
52 Week Range | 21.19 - 31.34 EUR |
Volume | 19 EUR |
Avg. Volume | 0 EUR |
Market Cap | 4.86B EUR |
Beta (5Y Monthly) | 0.605281 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 2.85 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 26.5 EUR |
8AK.F Valuation Measures
Enterprise Value | 4.58B EUR |
Trailing P/E | N/A |
Forward P/E | 22.519686 |
PEG Ratio (5 yr expected) | -3.41 |
Price/Sales (ttm) | 4.3327465 |
Price/Book (mrq) | 4.722589 |
Enterprise Value/Revenue | 4.084 |
Enterprise Value/EBITDA | -53.358 |
Trading Information
Alkermes plc Stock Price History
Beta (5Y Monthly) | 0.605281 |
52-Week Change | 13.47% |
S&P500 52-Week Change | 20.43% |
52 Week High | 31.34 EUR |
52 Week Low | 21.19 EUR |
50-Day Moving Average | 26.81 EUR |
200-Day Moving Average | 24.68 EUR |
8AK.F Share Statistics
Avg. Volume (3 month) | 0 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 166.12M |
Float | 149.71M |
Short Ratio | N/A |
% Held by Insiders | 1.75% |
% Held by Institutions | 103.16% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 2:1 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -14.64% |
Operating Margin (ttm) | -14.55% |
Gross Margin | 80.47% |
EBITDA Margin | -7.65% |
Management Effectiveness
Return on Assets (ttm) | -5.22% |
Return on Equity (ttm) | -15.78% |
Income Statement
Revenue (ttm) | 1.12B EUR |
Revenue Per Share (ttm) | 6.83 EUR |
Quarterly Revenue Growth (yoy) | 3.20% |
Gross Profit (ttm) | 893.69M EUR |
EBITDA | -85795000 EUR |
Net Income Avi to Common (ttm) | -164208992 EUR |
Diluted EPS (ttm) | -0.93 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 600.46M EUR |
Total Cash Per Share (mrq) | 3.62 EUR |
Total Debt (mrq) | 394.05M EUR |
Total Debt/Equity (mrq) | 39.19 EUR |
Current Ratio (mrq) | 2.252 |
Book Value Per Share (mrq) | 6.056 |
Cash Flow Statement
Operating Cash Flow (ttm) | -21936000 EUR |
Levered Free Cash Flow (ttm) | 34.39M EUR |
Profile of Alkermes plc
Country | Germany |
State | N/A |
City | Dublin |
Address | Connaught House |
ZIP | D04 C5Y6 |
Phone | 353 1 772 8000 |
Website | https://www.alkermes.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 2280 |
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence, and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Q&A For Alkermes plc Stock
What is a current 8AK.F stock price?
Alkermes plc 8AK.F stock price today per share is 23 EUR.
How to purchase Alkermes plc stock?
You can buy 8AK.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Alkermes plc?
The stock symbol or ticker of Alkermes plc is 8AK.F.
Which industry does the Alkermes plc company belong to?
The Alkermes plc industry is Drug Manufacturers-Specialty & Generic.
How many shares does Alkermes plc have in circulation?
The max supply of Alkermes plc shares is 167.08M.
What is Alkermes plc Price to Earnings Ratio (PE Ratio)?
Alkermes plc PE Ratio is 8.07017600 now.
What was Alkermes plc earnings per share over the trailing 12 months (TTM)?
Alkermes plc EPS is 2.85 EUR over the trailing 12 months.
Which sector does the Alkermes plc company belong to?
The Alkermes plc sector is Healthcare.